Omeros wins FDA breakthrough designation for novel biologic

27 April 2018
2019_biotech_test_vial_discovery_big

Washington, USA-based Omeros (Nasdaq: OMER) has been granted Breakthrough Therapy designation for its candidate OMS721, a treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) patients.

Shares in the firm jumped 7% in mid-afternoon trading yesterday, as news of the US Food and Drug Administration’s decision was announced. The decision means Omeros will benefit from expedited development and review treatment from the FDA.

It is the second Breakthrough drug designation for OMS721, which last year received the designation from FDA for the treatment of Immunoglobulin A (IgA) nephropathy.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology